Objective: To assess whether histamine type 2 receptor antagonists (H2RAs) improve overall survival when used as pre-, peri-, or postoperative therapy in patients with colorectal cancer who had surgical resection with curative intent.
Members Only
Access to this article is restricted. Please log in to view the full article.